Functional gastrointestinal disorders affect approximately 40 million people in the United States, and the toll in terms of burden of disease on individuals and the healthcare system is significant. Patients and clinicians alike are not satisfied with traditional treatment options, and it is hoped that recent and emerging additions to the therapeutic armamentarium will improve outcomes. Taryn Brill hosts this series of expert perspectives by a leader in the field of irritable bowel syndrome, who will explore treatment options for patients with functional disorders of constipation and diarrhea.